Disease
Kidney cancer肾癌
ICD-10: C64 — Malignant neoplasm of kidney, except renal pelvis
Key figures
Published values only. Every tile opens the section that carries its source, its year and its caliber.
Disease details
- Standard Chinese name
- 肾癌
- English name
- Malignant neoplasm of kidney, except renal pelvis
Values written in Chinese are quoted as published by the source.
Also known as
- Renal cell carcinoma
- Renal cancer
Treatment cost ranges
Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.
| Treatment path | Cost range | Price basis | Data year |
|---|---|---|---|
| Surgery 手术 | 36000 – 36000 CNY | Condition package price 病种打包全包价 | 2020 |
The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 36000 CNY. Each row keeps its own data year and caliber.
1 cost range for this condition, with its source on the row page.
Values written in Chinese are quoted as published by the source.
Five-year survival
5-year survival rate 65.2% 95% CI 64.6–65.7
- Population
- Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
- Period
- 2019–2021
- Publisher
- National Cancer Center 国家癌症中心
- Value nature
- Estimated value (hybrid analysis) 估计值（混合法）
- Registry scope
- 281 population-based cancer registries 281 个肿瘤登记处
- Stage data availability
- Not published
Values written in Chinese are quoted as published by the source.
How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.
The figure is relative survival: it compares people diagnosed with this cancer against people of the same age and sex in the general population, and it is age-standardised, so it is not the share of patients still alive after five years. It is published as an estimated value (hybrid analysis) because registry reports arrive with a lag, so the National Cancer Center modelled the most recent period. For context, the same source publishes 43.7% five-year relative survival for all cancers combined in 2019–2021.
Hospitals with a published record for this condition
Selected using official public data sources
These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.
How these hospitals were selected
Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.
Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.
Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.
When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.
The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.
-
Chinese PLA General Hospital中国人民解放军总医院
Fudan specialty reputation ranking 2023
- Urology #1 https://www.fdygs.com/news2023-1.aspx
Also ranked: General Surgery #5, Otorhinolaryngology #3, Gastroenterology #4 in the Fudan list.
-
West China Hospital, Sichuan University四川大学华西医院
Fudan specialty reputation ranking 2023
- Urology #2 (tied) https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Also ranked: General Surgery #3, Thoracic Surgery #4, Otorhinolaryngology #8 in the Fudan list.
-
Peking University First Hospital北京大学第一医院
Fudan specialty reputation ranking 2023
- Urology #2 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level B) https://www.pkufh.com/Html/News/Articles/64494.html
Also ranked: Infectious Diseases 传染感染 #9, General Surgery nominated, Gynecology nominated in the Fudan list.
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院
Fudan specialty reputation ranking 2023
- Urology #4 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level B) https://www.gzsys.org.cn/basic/453
Also ranked: General Surgery nominated, Gynecology nominated, Otorhinolaryngology nominated in the Fudan list.
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院
Fudan specialty reputation ranking 2023
- Urology #5 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level B) https://www.tjh.com.cn/contents/934/27291.html
Also ranked: General Surgery #6, Gynecology #2, Respiratory Medicine #8 in the Fudan list.
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine上海交通大学医学院附属仁济医院
Fudan specialty reputation ranking 2023
- Urology #6 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level B) https://www.renji.com/gh/article/list/01/01
Also ranked: Gynecology #10, Gastroenterology #1, Nuclear Medicine 核医学 #8 in the Fudan list.
-
Peking Union Medical College Hospital中国医学科学院北京协和医院
Fudan specialty reputation ranking 2023
- Urology #8 https://www.fdygs.com/news2023-1.aspx
Also ranked: General Surgery #1, Gynecology #1, Otorhinolaryngology #4 in the Fudan list.
-
The First Affiliated Hospital, Zhejiang University School of Medicine浙江大学医学院附属第一医院
Fudan specialty reputation ranking 2023
- Urology #9 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Urology (level A) http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Also ranked: General Surgery #7, Infectious Diseases 传染感染 #2, Thoracic Surgery nominated in the Fudan list.
Clinical trials (investigational treatments)
In addition to standard care, clinical research studies for Kidney cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.
-
Study Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Recruiting
- Registry
- NCT06956144
-
Study Evaluation of Diagnostic Value of 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
- Lead investigator
- GONG Kan · Surgeon
- Hospital
- Peking University First Hospital
- Status
- Recruiting
- Registry
- NCT06519760
-
Study Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
- Hospital
- Peking University First Hospital
- Status
- Recruiting
- Registry
- NCT07166445
-
Study A Prospective, Multicenter Study of Diagnostic Efficiency of 68Ga-PSMA PET in the Patients With Locally Advanced and Advanced Renal Cell Carcinoma
- Lead investigator
- Qin Weijun · Professor and Director, Department of Urology
- Hospital
- Shaanxi Provincial People's Hospital
- Status
- Recruiting
- Registry
- NCT04987086
-
Study Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma
- Lead investigator
- Li Zhang · associate professor
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Recruiting
- Registry
- NCT05214885
6 more registered studies
-
Study Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
- Lead investigator
- Jie Ding · Attending doctor
- Hospital
- XinHua Hospital
- Status
- Recruiting
- Registry
- NCT04113486
-
Study Cohort Study of SABR Combined With Targeted Therapy and Anti-PD-1 Versus Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cell Carcinoma Patients
- Hospital
- Peking University First Hospital
- Status
- Recruiting
- Registry
- NCT06583070
-
Study A Clinical Study to Evaluate the Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Patients With Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
- Lead investigator
- Han weidong · Director of Biotherapeutic Department
- Hospital
- Chinese PLA General Hospital
- Status
- Recruiting
- Registry
- NCT07645690
-
Study This is a Single-center, Single-arm, Phase II, Prospective Clinical Study Planning to Enroll 30 Patients With Advanced Renal Cell Carcinoma. Eligible Patients, After Signing the Informed Consent Form and Passing the Screening Process, Will Receive Envafolimab + Axitinib Treatment Until Disease Progression or Intolerable Toxicity (Treatment Duration Not Exceeding 24 Months). Clinical Tumor Imaging Assessments Will be Conducted Every 12 Weeks During the Treatment Process According to the RECIST V1.1 Criteria. Safety Will be Assessed Using CTCAE 5.0, With Adverse Events Recorded From Each Treatme
- Hospital
- Peking Union Medical College Hospital
- Status
- Not yet recruiting
- Registry
- NCT07159191
-
Study A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma
- Lead investigator
- Jun Guo · MD
- Hospital
- Peking University Cancer Hospital
- Status
- Not yet recruiting
- Registry
- NCT06472895
-
Study The Efficacy and Safety of Cardonilizumab Combined With Lenvastinib in Perioperative Treatment of Resectable Renal Clear Cell Carcinoma-A Single-arm, Single-center, Exploratory Clinical Study
- Lead investigator
- Ziling Liu · Principal Investigator
- Hospital
- The First Hospital of Jilin University
- Status
- Not yet recruiting
- Registry
- NCT06574412
This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.
Hospitals with a national key specialty record
Show the hospital records 30 hospitals with a key-specialty record
Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.
30 hospitals with a matching national key specialty record.
Values written in Chinese are quoted as published by the source.
What patients report
Aggregate figures only: a national result quoted with its source and the year it refers to. This is not a patient testimonial and not a statement about one person.
As reported in National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023): National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.
National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).
Source: National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Level A
Questions about this condition
We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.
ICD codes
Show the code table 1 ICD code
| Version | Code | Name in that version |
|---|---|---|
| ICD-10-WHO | C64 | Malignant neoplasm of kidney, except renal pelvis |
Rows are the WHO ICD-10 entries for this condition, quoted as published.
Source & evidence
- Source URL
- https://qzybj.quanzhou.gov.cn/qt/gzcx/bzsfcx/202006/P020221216571645625406.pdf
- Source scheme
- https
- Source type
- Provincial health commission
- Evidence level
- A - stated by a health commission, a national research institute or a university
- Retrieved on
- 2026-09-30